First Analysis
http://www.firstanalysis.com/index.asp?PID=16First Analysis is an investment organization specializing in private equity, venture capital, investment banking, and equity research. The sectors in the firm’s coverage universe include outsourced services, IT products and services, and chemistry-enabled businesses. First Analysis was founded in 1981.
View Older Stories View More Recent Stories
-
New nference COVID-19 Study and Online Tracker First to Produce Evidence of Increased COVID-19 Vaccinations on Decreased Viral Incidence by US Counties
-
In boost for COVID-19 battle, Pfizer vaccine found 94% effective in real world
-
Appdetex Accelerates Growth with $12.2 Million Financing Led by Baird Capital
-
Leading Insurance Software Company PCMI Announces Investment from Equality Asset Management to Accelerate Growth
-
Explainer-Where are we in the COVID-19 vaccine race?
-
Explainer-Where are we in the COVID-19 vaccine race?
-
Hepion Pharmaceuticals (HEPA) Reports DSMB Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients
-
BioMarin Pharma (BMRN) Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
-
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
-
Explainer-Where are we in the COVID-19 vaccine race?
-
Q&A: Where are we in the COVID-19 vaccine race?
-
Oxford University breakthrough on global COVID-19 vaccine
-
Oxford University breakthrough on global COVID-19 vaccine
-
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
CIBC Innovation Banking provides debt financing to Yello, Inc.
-
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
-
Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
-
Moderna closes in on release of COVID-19 vaccine data
-
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
-
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
-
Q&A: Where are we in the COVID-19 vaccine race?
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Shows Over 90% Efficacy in Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports
-
Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care
-
Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care
-
"COVID-19: The Greatest Cover Up In History - From Wuhan To The White House" Exposes Government Corruption & Malfeasance
-
observIQ Launches Powerful New Full Stack Log Management Platform to Beta
-
Pfizer vaccine trial bets on early win against coronavirus, documents show
-
How drugmakers can keep their pledge and still deliver an October vaccine surprise
-
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine
-
Mediant Announces $18.5 Million Equity Infusion To Support Next Phase Of Growth
-
William Blair Expands Equity Capital Markets Investment Banking Team, Adding Brian Friedman in Chicago
-
GenSight Biologics Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation
-
Blue Medora Launches observIQ
-
Food commodities still at risk of coronavirus 'market shock' -FAO/OECD
-
Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
-
Abbott (ABT) Announces New Late-Breaking Data Highlight Impact of its Minimally Invasive Structural Heart Therapies
-
New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies
-
New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting
-
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
-
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
-
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
-
Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO
-
Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO

